Humacyte (HUMA) Interest Expenses (2020 - 2026)
Humacyte (HUMA) posted quarterly Interest Expenses of $2.3 million for Q1 2026, down 24.3% year-over-year from $3.0 million in Q1 2025, and up 287.54% quarter-over-quarter from $586000.0 in Q4 2025.
Humacyte (HUMA) Interest Expenses (2020 - 2026) Analysis & Trends
Humacyte (HUMA) has reported Interest Expenses for 7 consecutive years, with $2.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Interest Expenses fell 24.3% year-over-year to $2.3 million; the TTM figure through Mar 2026 stood at $8.4 million (down 16.42% YoY), while the FY2025 annual figure was $11.2 million, down 93.85% from the prior year.
- Interest Expenses rose to $2.3 million in Q1 2026 per HUMA's latest filing, from $586000.0 in the prior quarter.
- Across five years, Interest Expenses topped out at $62.2 million in Q3 2025 and bottomed at $586000.0 in Q4 2025.
- Historically, Interest Expenses has averaged $6.0 million across 5 years, with a median of $2.1 million in 2024.
- Annual changes were most pronounced in 2022 — Interest Expenses plunged 93.86% — and 2025, when it jumped 2451.97%.
- Humacyte's Interest Expenses stood at $1.6 million in 2022, then jumped by 204.21% to $5.0 million in 2023, then slumped by 57.88% to $2.1 million in 2024, then plunged by 72.1% to $586000.0 in 2025, then jumped by 287.54% to $2.3 million in 2026.
- Business Quant data shows HUMA's Interest Expenses at $2.3 million in Q1 2026, $586000.0 in Q4 2025, and $62.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.52 Bn | 132.67 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 86.54 Bn | 78.55 Bn | 3.93 Bn | 11.00 Mn |
| 3 | Argenx Se | 65.31 Bn | 60.13 Bn | 1.37 Bn | - |
| 4 | Moderna | 61.77 Bn | 56.64 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 42.26 Bn | 37.16 Bn | 1.53 Bn | 39.74 Mn |
| 6 | Alnylam Pharmaceuticals | 31.19 Bn | 27.88 Bn | 992.69 Mn | 82.05 Mn |
| 7 | BioNTech SE | 28.71 Bn | 10.31 Bn | 668.28 Mn | -4.89 Mn |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 20.27 Mn |
| 9 | Royalty Pharma | 27.35 Bn | 26.52 Bn | - | 93.62 Mn |
| 10 | Humacyte | 153.62 Mn | 153.62 Mn | -825,000.00 | 2.32 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.32 Mn |
| Jun 30, 2026 | 2.32 Mn |
| Mar 31, 2026 | 2.27 Mn |
| Mar 31, 2026 | 2.27 Mn |
| Dec 31, 2025 | 586,000.00 |
| Dec 31, 2025 | 586,000.00 |
| Sep 30, 2025 | 62.22 Mn |
| Sep 30, 2025 | 62.22 Mn |
| Jun 30, 2025 | 2.55 Mn |
| Jun 30, 2025 | 2.55 Mn |
| Mar 31, 2025 | 3.00 Mn |
| Mar 31, 2025 | 3.00 Mn |
| Dec 31, 2024 | 2.10 Mn |
| Dec 31, 2024 | 2.10 Mn |
| Sep 30, 2024 | 2.44 Mn |
| Sep 30, 2024 | 2.44 Mn |
| Jun 30, 2024 | 2.52 Mn |
| Jun 30, 2024 | 2.52 Mn |
| Mar 31, 2024 | 1.82 Mn |
| Mar 31, 2024 | 1.82 Mn |